Updates of non-biologic therapies in the era of biologics
O. Zargari
PARS Clinic, Rasht, Iran

Our understanding of the pathogenesis of psoriasis has been changed considerably over the last past years. In parallel with this, a new class of agents, called “biologics”, has been added to the armamentarium of psoriasis therapies.
Although, the biologics are perhaps the most promising of available psoriasis treatments, they have their own draw backs. Costs, unknown-long term complications, rebound and even paradoxical induction of psoriasis are among the major disadvantages of biologics.
During the past decade, a remarkable progress has been also achieved in the field of “Non-biological” therapies for psoriasis. In this presentation, I will update our data about these therapies in three sections: 1) Updates in traditional therapies with focus on methotrexate. 2) New agents and developments while focusing on Retinoic Acid Metabolism-Blocking Agents (RAMBAs) and new derivatives of vitamin D. 3) Non-standard and off-label therapies.